794 related articles for article (PubMed ID: 9489629)
1. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
[TBL] [Abstract][Full Text] [Related]
4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
7. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
8. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
11. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.
Ria R; Falzetti F; Ballanti S; Minelli O; Di Ianni M; Cimminiello M; Vacca A; Dammacco F; Martelli MF; Tabilio A
Hematol J; 2004; 5(2):118-22. PubMed ID: 15048061
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
13. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
14. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Clark AD; Douglas KW; Mitchell LD; McQuaker IG; Parker AN; Tansey PJ; Franklin IM; Cook G
Br J Haematol; 2002 Jun; 117(3):605-12. PubMed ID: 12028028
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
18. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
19. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
20. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
